|
|
|
Providers > About LungSign™
|
About LungSign™
|
|
|
LungSign™ — new hope for early detection
LungSign™ is a safe, painless and convenient test to assess a
patient's rist of lung cancer. LungSign™ is based on an innovative
marker in sputum that is highly correlated with the presence of lung
malignancy — even in early stage presymtomatic disease.
As Such, LungSign™ is the first test to market that provides both
an independent result to help with the early detection of lung cancer
and a useful compliment to current radiological diagnostic methods. For
example, LungSign™ can be used to further define the cancer risk
of patients with small CT-detected nodules, by adding a biological measure
of malignancy.
The patients for whom LungSign— is expected to benefit include:
-
Patients suspicious for lung cancer (see indications below) or those
being considered for CT screening
-
Post-CT patients seeking assessment of malignant potential of nodules
of undetermined significance
-
Patients for whom radiation from CT or x-ray should be limited (e.g.,
women at risk for breast cancer, female smokers, or lung cancer survivors
-
Lung cancer survivors monitoring for recurrence
-
Patients in need of motivation-related smoking cessation tools
Indications for use
LungSign™ is indicated for the evaluation of high risk patients
suspicious for lung cancer due to their:
-
Age — over 50 years
-
Significant smoking history (over 20 pack-years) or significant exposure
to carcinogens
-
Symtomology or clinical suspicion for lung cancer
LungSign™ may benefit high-risk patients of both sexes in particular:
smokers, former smokers, and individuals exposed to industrial and environmental
carcinogens.
LungSign™ has not been validated for patients who have recieved
chemotherapy or radiotherapy. In addition, it has not been validated for
patients who harbor cancers other than lung cancer.
LungSign™ in Practice
LungSign™ should be requested and interpreted under the care of a
physician. LungSign™ sample collection kits are orderable at
Order LungSign™ Now
.
The LungSign™ test consists of a sputum specimen collection kit
(used by patients in the privicy of their homes), and, after the laboratory
analysis is complete, a specimen testing report and interpretation guide,
sent directly to the patient's physician. The turn-around for delivery of
reports is typically two weeks.
next >
|
|
|
| |
Perceptronix is a cancer diagnostic service company focused on detecting cancer
at early stages to improve patient outcomes.
|
|
|
